Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review.
about
Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapyPerillyl Alcohol and Its Drug-Conjugated Derivatives as Potential Novel Methods of Treating Brain MetastasesLow-dose oxytocin delivered intranasally with Breath Powered device affects social-cognitive behavior: a randomized four-way crossover trial with nasal cavity dimension assessment.Airflow in the Human Nasal Passage and Sinuses of Chronic Rhinosinusitis Subjects.Numerical optimization of targeted delivery of charged nanoparticles to the ostiomeatal complex for treatment of rhinosinusitis.Analytical challenges and regulatory requirements for nasal drug products in europe and the u.s.Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powderA randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study).High resolution visualization and analysis of nasal spray drug delivery.Types of nasal delivery drugs and medications in Iranian traditional medicine to treatment of headache.Bolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus: Guided Formulation Development for a Nasal Ebola VaccineA Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola InfectionDry powder nasal drug delivery: challenges, opportunities and a study of the commercial Teijin Puvlizer Rhinocort device and formulation.Evaluating the therapeutic efficacy, tolerability, and safety of an aqueous extract of Costus speciosus rhizome in acute pharyngitis and acute tonsillitis. A pilot study.AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacksA long-lasting, single-dose nasal vaccine for Ebola: a practical armament for an outbreak with significant global impactA role for autonomic cardiac control in the effects of oxytocin on social behavior and psychiatric illnessSinonasal Delivery of Resveratrol via Mucoadhesive Nanostructured Microparticles in a Nasal Polyp Mouse Model.Respiratory allergies: a general overview of remedies, delivery systems, and the need to progressBreath powered nasal delivery: a new route to rapid headache relief.The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview.A novel intranasal breath-powered delivery system for sumatriptan: a review of technology and clinical application of the investigational product AVP-825 in the treatment of migraine.Oxytocin effects in schizophrenia: Reconciling mixed findings and moving forward.Is RPMI 2650 a Suitable In Vitro Nasal Model for Drug Transport Studies?Current prospects and future challenges for nasal vaccine delivery.Pharmacokinetics after a single dose of naloxone administered as a nasal spray in healthy volunteers.Challenges in nasal drug absorption: how far have we come?Emerging delivery platforms for mucosal administration of biopharmaceuticals: a critical update on nasal, pulmonary and oral routes.Hydrogel nanoparticles and nanocomposites for nasal drug/vaccine delivery.Is There an Optimal Formulation and Delivery Strategy for Subunit Vaccines?Impact of airborne particle size, acoustic airflow and breathing pattern on delivery of nebulized antibiotic into the maxillary sinuses using a realistic human nasal replica.AVP-825: a novel intranasal delivery system for low-dose sumatriptan powder in the treatment of acute migraine.Accessing the brain: the nose may know the way.Amphotericin B deoxycholate nasal spray administered to hematopoietic stem cell recipients with prior fungal colonization of the upper airway passages is associated with low rates of invasive fungal infection.Preliminary study of nanonized lamotrigine containing products for nasal powder formulation.Dose-dependent social-cognitive effects of intranasal oxytocin delivered with novel Breath Powered device in adults with autism spectrum disorder: a randomized placebo-controlled double-blind crossover trial.Absorption and Clearance of Pharmaceutical Aerosols in the Human Nose: Effects of Nasal Spray Suspension Particle Size and Properties.Numerical Comparison of Nasal Aerosol Administration Systems for Efficient Nose-to-Brain Drug Delivery.Intranasal immunization with dry powder vaccines.
P2860
Q26801545-FD56CA25-5892-487F-A41D-41EAC4E34881Q28072442-7228C795-A7D8-4CB8-B2EE-FA504981D314Q30372084-EF9A7078-5F27-4104-A576-7239A016A465Q30381696-A19BF69C-DC3F-4697-9436-19C5D935752DQ30405161-9DC80FF3-8C0D-4D15-9E27-7DFF95F0D29FQ33858659-2FBBFAC8-38C6-4C06-87D9-A80A6BDED94DQ34383339-87773E22-0F91-4DA1-9700-23C43E13FA0DQ34512817-BFACD855-BFFF-4BDD-B556-0F989B395651Q35061116-C6D0E9D9-46B9-44C7-8EE2-536BFFB4DE05Q35097008-89B0E9E7-7B3B-4939-A38F-3D104417F42FQ35213990-792507FA-C605-4B36-8F75-385F6D0B0276Q35917496-97030D55-3CD9-4A86-9A45-757FBF39134FQ35917501-38D0720A-20B6-462A-8E00-C17FD252CFF9Q35948724-5AD908FE-FF8C-4B07-878E-701D8EB2D7E7Q35996267-6CA57CE7-DC4F-4293-B8CE-285DAD161434Q36380205-DAFFA344-BC96-43F0-9C62-907EACA6FF7AQ36474341-F2A40139-15D7-427B-8F77-C786CB1CAE03Q36733024-C21FCE32-2905-49C5-BA69-5182C616CAF5Q37575958-81B22883-B180-438D-BE78-C8AD0DA0006AQ37679681-69BC817B-731F-4404-9903-E7AB2365456CQ38136260-94491D1B-C13C-4B5E-B667-9D2CD0A910A7Q38236698-861F580D-2F38-4325-9DE6-F070841F9EF0Q38539637-607271A6-4EEB-4FC9-AC1B-8E3755454FBFQ38683538-7427F021-C07A-4036-AACC-20C21CFADDC5Q38688723-5BF2348C-131C-4685-8486-0509073C269FQ38784950-46BB39A7-80BD-4885-B09D-165309C4C889Q38818902-8B4DD16E-0277-4FC0-9D7A-D72A7E06107CQ38842805-C7A0D791-C847-400D-9121-82D3A82E72A2Q38847705-F8E38EDE-23A6-4FF7-AB8B-56B6834198A3Q38879581-7F562955-9E9A-4AA1-8438-C55B13A3B46EQ38886698-66612AD5-A7C4-48BD-A78B-58AAFAB4E747Q39240113-11499EA8-BFE5-45E2-81E8-001FBB64961DQ39366862-4385422D-55BD-4A14-AACE-2777EE7DD82FQ40661375-85C66539-FAC8-4C31-8811-3F044019D07BQ41522694-0FE2D035-8623-4AFD-9FD1-250B64677332Q41545495-5BBC207E-16F4-4A2A-8AB8-7C9DAFF6020BQ41614659-E9E4C8BA-C878-4141-8D04-148447EE924BQ45023809-CC24E98C-45E0-4694-AF15-0D61E4C0C005Q47210467-8B25B1F3-C2A5-460C-AE32-85276D3619C8Q47584590-71616C7B-4F2F-47B2-AD22-57BF84317A92
P2860
Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Nasal drug delivery devices: c ...... clinical perspective-a review.
@ast
Nasal drug delivery devices: c ...... clinical perspective-a review.
@en
type
label
Nasal drug delivery devices: c ...... clinical perspective-a review.
@ast
Nasal drug delivery devices: c ...... clinical perspective-a review.
@en
prefLabel
Nasal drug delivery devices: c ...... clinical perspective-a review.
@ast
Nasal drug delivery devices: c ...... clinical perspective-a review.
@en
P2860
P1476
Nasal drug delivery devices: c ...... clinical perspective-a review.
@en
P2093
Per Gisle Djupesland
P2860
P2888
P356
10.1007/S13346-012-0108-9
P577
2012-10-18T00:00:00Z
P5875
P6179
1032684388